ArticleNPJ precision oncology2026
Hybrid supervised deep learning for lung adenocarcinoma diagnosis to optimize surgical strategies.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intraoperative frozen section pathological diagnosis of lung adenocarcinoma serves as the gold standard for determining the extent of surgical resection. Due to the dual constraints of intraoperative time limitations and the challenge of manually assessing tumor invasion volume in three-dimensional space, current manual diagnostic approaches and weakly supervised deep learning methods have demonstrated suboptimal diagnostic accuracy. To enhance the accuracy of intraoperative pathological diagnosis of lung adenocarcinoma and provide more precise recommendations for intraoperative resection extent to thoracic surgeons, we have developed a Hybrid-Supervised Framework for Lung Adenocarcinoma (HSFLA). This framework accomplishes the following processes: hybrid-supervised diagnosis of 2D whole slide images (WSIs), automatic annotation of tumor invasive regions, registration of consecutive WSIs, and 3D reconstruction and volume calculation of tumor invasive areas. We evaluated HSFLA on a dataset comprising 1161 WSIs from two centers and three subtypes, achieving an accuracy of 95.6%, which represents a significant improvement over manual review (84.7%) and weakly supervised learning (66.2% ± 3.0%). The consistency of its invasive area automatic annotations with manual pixel annotations was 86.6%. Furthermore, HSFLA's concordance with spatial transcriptomics samples demonstrated its interpretability at the genetic level. Utilizing HSFLA's automatic annotation functionality provided pathologists with a safe and effective diagnostic aid, improving their manual diagnostic accuracy by 22.9% (n = 3). We also applied HSFLA in real-world clinical settings for prospective study. Compared to manual diagnosis alone, the "human-machine interaction" diagnostic mode provided more appropriate surgical recommendations for 5 patients (among 70). Overall, HSFLA demonstrates the potential clinical utility of artificial intelligence in supporting intraoperative pathological assessment and surgical decision-making, and may serve as a paradigm for future innovations in AI-assisted clinical workflows.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.